BI-505 is a human monoclonal IgG1 antibody with high specificity for ICAM-1, selected by functional screening for its ability to induce dose-dependent programmed cell death in B lymphoma cell lines [32] and with promising anti-myeloma activity in several murine myeloma models including hu-SCID mice with human fetal bone chip and human primary myeloma cells [15, 16]. This evidence concerns the gene ICAM1 and plasma cell myeloma.